The performance metrics speak volumes. The iShares Biotechnology ETF (NASDAQ: IBB) has climbed 29.51% year to date through December 29, while the State Street SPDR S&P Biotech ETF (NASDAQ: XBI) has ...

Shares of the biotech stock fell through their 50-day and 200-day moving averages in volume that was tracking 4,000% above ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

Discover S&P 500 forecasts for 2025-2026, key market risks, and why pharmaceuticals may outperform. Click for more on my view ...

Biotech called the shots in the Bay Area’s year-end capital scramble, with the single largest sale in the region clocking in ...

Jarez Holz says 2026 will be a strong year for biotech stocks. The Mizuho analyst explained why in a recent CNBC interview.

One of the biotech industry’s most esteemed venture capitalists anticipates that, after two years of drought, a wave of drug ...

The biotech sector has been one of the market's laggards for several years now, and 2025 has been no different, at least on the surface. Year-to-date, the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB ...

California-based Foresite Capital Management VI sold 585,000 shares of Edgewise Therapeutics in the third quarter. The overall position value fell by about $7.67 million from the previous period. The ...

The MarketWatch News Department was not involved in the creation of this content. The biotechnology market is anticipated to expand at a rapid pace owing to high incidence of chronic diseases, growing ...